FDA Increasingly Halting Human Trials as Companies Pursue Risky, Cutting-Edge Drugs

[ad_1] Health Agency places more holds on trials to protect patients, ensure studies are designed properly, Wall Street Journal review finds [ad_2] Source link

AstraZeneca to Buy U.S. Cardiorenal-Drug Maker

[ad_1] For an initial $1.3 billion, the Anglo-Swedish company will acquire CinCor Pharma, including rights to its baxdrostat cardiorenal drug, which has shown promise in clinical trials. [ad_2] Source link

New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients

[ad_1] Health Medicare won’t pay for medicine under rule issued to restrict use of earlier drug whose approval generated controversy [ad_2] Source link

China’s New mRNA Covid Vaccine Targeting Omicron Starts Trial Production

[ad_1] Chinese drugmaker CanSino Biologics started trial production of a vaccine using mRNA technology to target new variants of Covid-19 that are behind the country’s current outbreak. [ad_2] Source link

China to Allow Rapid Tests to Confirm Covid Cases

[ad_1] World Asia China Beijing takes more steps to dismantle its zero-Covid policies [ad_2] Source link

China-Developed mRNA Covid Vaccine Starts Test Production

[ad_1] Chinese drugmaker CanSino Biologics started trial production of a vaccine using mRNA Technology to target new variants of Covid-19 that are behind the country’s current outbreak. [ad_2] Source link

New Biden Law Won’t Kill Drug Cures. It Will Reshape Them.

[ad_1] Legislation signed by the president in 2022 is likely to affect how pharmaceutical companies allocate capital [ad_2] Source link

To Bring the Old Boeing Back, Profit Isn’t Enough

[ad_1] The plane maker is understandably intent on generating cash, but the announcement that it won’t deliver any brand-new models until the mid-2030s spells worries about its long-term future [ad_2]…

Two Biotech CEOs Indicted on Securities Fraud Charges

[ad_1] The former chief executive of CytoDyn and the CEO of a company that managed its clinical trials allegedly made fraudulent claims about an experimental drug. [ad_2] Source link

Surprising Fatty Liver Results Could Put Madrigal in Big Pharma’s Sights

[ad_1] Markets Heard on the Street Better-than-expected trial results for company’s NASH treatment could rekindle interest in this disease area [ad_2] Source link